Skip to main content
Donate
Current Pipeline
FAST Logo Funded
BDNF

Brown

Brown University is exploring an investigational Brain-Derived Neurotrophic Factor (BDNF) approach to treating Angelman syndrome.

Pre-clinical

Discovery & Dev

Pre-clinical

Phase 1

Phase 2

Phase 3

To patients

  • progress mobile progress mobile progress mobile progress mobile progress mobile progress mobile

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.

Therapeutic Approach

A therapeutic approach using a small molecule to improve synapse function by addressing BDNF signaling (Brain-Derived Neurotropic Factor), which has been shown to be abnormal in Angelman syndrome neurons. This approach improves the communication between two neurons, which is impacted in AS.

Investigational Drug Name

SYN-3

Recent Updates

  • July 2024

    A new publication represents a possible small-molecule approach to potentially treat the synaptic dysfunction observed in Angelman syndrome.

    Read More
  • June 2024

    Finding novel treatments for Angelman syndrome: Could Syn3 be the answer?

    Read More

Media

  • Development of a Drug that Strengthens Synaptic Connections for the Potential Treatment of Angelman Syndrome: The Role of BDNF

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.